Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study
RHHBY reports that giredestrant plus palbociclib misses the main PFS goal in a phase III first-line breast cancer study, though the combo shows a numerical improvement.
Zacks·18h ago
More News
Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal
RHHBY says the ZUPREME-1 study meets its goal as petrelintide delivers up to 10.7% weight loss with placebo-like tolerability, supporting further advancement.
Zacks·4d ago
Merck (MRK) Up 1.7% Since Last Earnings Report: Can It Continue?
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·5d ago
Corcept's Korlym Drives its 2025 Revenue Surge: What's Ahead?
CORT's Korlym 2025 sales rises 13% Y/Y, with 2026 revenues seen at $900M-$1B. However, the court ruling favoring Teva's generic may put pressure on future sales.
Zacks·5d ago
Merck's Keytruda Drives its 2025 Revenue Surge: What's Ahead?
MRK's Keytruda posted $31.7B in 2025 sales. Can new approvals, ongoing studies and a revamped structure keep oncology growth strong through 2026?
Zacks·7d ago
Roche's BTK Drug Fenebrutinib Shines in Multiple Sclerosis Study
RHHBY's fenebrutinib slashes RMS relapses by 51% in phase III, advancing its bid for a first high-efficacy oral therapy in MS.
Zacks·7d ago
Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates
SRPT posts a wider Q4 loss as Elevidys sales tumble, but revenues top estimates and 2026 guidance outlines a cautious recovery path.
Zacks·12d ago
The Zacks Analyst Blog Highlights Costco Wholesale, Roche, Lam Research, Spruce Power and IDT
Costco, Roche and Lam Research lead Zacks??? top stock reports, with standout gains and resilient fundamentals across sectors.
Zacks·13d ago
Top Stock Reports for Costco, Roche & Lam Research
Costco's resilient membership model, strong cash flow and e-commerce momentum position it to weather market turmoil and keep earnings growing.
Zacks·13d ago
FDA Accepts Roche's NDA Seeking Approval for Breast Cancer Drug
FDA's acceptance of RHHBY's NDA for giredestrant plus everolimus in ER-positive breast cancer sets up a potential first oral SERD combo.